These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14521422)

  • 1. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
    Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
    J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.
    Wang H; Yu N; Song H; Chen D; Zou Y; Deng W; Lye PL; Chang J; Ng M; Sun ET; Sangthongpitag K; Wang X; Wu X; Khng HH; Fang L; Goh SK; Ong WC; Bonday Z; Stünkel W; Poulsen A; Entzeroth M
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1403-8. PubMed ID: 19181524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
    Mahboobi S; Sellmer A; Höcher H; Garhammer C; Pongratz H; Maier T; Ciossek T; Beckers T
    J Med Chem; 2007 Sep; 50(18):4405-18. PubMed ID: 17691763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
    Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
    J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
    Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
    J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
    Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M
    J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
    Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
    Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
    Mai A; Massa S; Ragno R; Cerbara I; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2003 Feb; 46(4):512-24. PubMed ID: 12570373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
    Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
    J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
    Atadja P; Hsu M; Kwon P; Trogani N; Bhalla K; Remiszewski S
    Novartis Found Symp; 2004; 259():249-66; discussion 266-8, 285-8. PubMed ID: 15171259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
    Ragno R; Mai A; Massa S; Cerbara I; Valente S; Bottoni P; Scatena R; Jesacher F; Loidl P; Brosch G
    J Med Chem; 2004 Mar; 47(6):1351-9. PubMed ID: 14998325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
    Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
    Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
    Lee S; Shinji C; Ogura K; Shimizu M; Maeda S; Sato M; Yoshida M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4895-900. PubMed ID: 17588744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
    Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
    J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.
    Paquin I; Raeppel S; Leit S; Gaudette F; Zhou N; Moradei O; Saavedra O; Bernstein N; Raeppel F; Bouchain G; Fréchette S; Woo SH; Vaisburg A; Fournel M; Kalita A; Robert MF; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; MacLeod AR; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1067-71. PubMed ID: 18160287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.